Новости
хирургии
Журнал включен
в систему цитирования Scopus









2011 г. №3 Том 19

ЛЕКЦИИ, ОБЗОРЫ

И.И. МАЛИHОВСКАЯ

ИHГИБИТОРЫ ФАКТОРА РОСТА ЭHДОТЕЛИЯ СОСУДОВ В ЛЕЧЕHИИ ДИАБЕТИЧЕСКОГО МАКУЛЯРHОГО ОТЕКА

ГУО «Белорусская медицинская академия последипломного образования»,
Республика Беларусь

Диабетическая ретинопатия и ее проявление, диабетический макулярный отек являются одной из ведущих причин слепоты во всем мире. В последнее десятилетие появилось много работ, доказывающих основную роль фактора роста эндотелия сосудов (VEGF) в этиопатогенезе этих заболеваний, влиянию его на развитие неоваскуляризации сетчатки и увеличению проницаемости сосудов. Данная статья посвящена результатам нового направления в лечении диабетического макулярного отека - интравитреальному введению ингибиторов VEGF.

Ключевые слова: диабетический макулярный отек, ингибиторы фактора роста эндотелия сосудов, антиангиогенная терапия
с. 118 – 125 оригинального издания
Список литературы
  1. Скоробогатова, Е. С. Инвалидность вследствие офтальмологических осложнений сахарного диабета в России / Е. С. Скоробогатова, Е. С. Либман // Тезисы докл. VIII съезда офтальмологов, Москва, 1–4 июня 2005 г. – М., 2005. – С. 88.
  2. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial Diabetic Retinopathy Vitrectomy Study report 3 / Diabetic Retinopathy Vitrectomy Study Research Group // Ophthalmology. – 1988. – Vol. 95. – P. 1307-1320.
  3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 / Early Treatment Diabetic Retinopathy Study Research Group // Arch. Ophthalmol. – 1985. – Vol. 103. – P. 1796-1806.
  4. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic Macular Edema / R. Klein [et al.] // Ophthalmology. – 1984. – Vol. 91. – P. 1464-1474.
  5. Ferris, F. Macular edema: a complication of diabetic retinopathy / F. Ferris, A. Patz // Surv. Ophthalm. – 1984. – Vol. 28. – P. 452-461.
  6. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor / L. Aiello [et al.] // Diabetes. – 1997. – Vol. 46. – P. 1473-1480.
  7. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family / F. R. Steele [et al.] // Proc. Natl. Acad. Sci. USA. – 1993. – Vol. 90. – P. 1526-1530.
  8. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor / K. Mori [et al.] // Invest. Ophthalmol. Vis. Sci. – 2002. – Vol. 43, N 7. – P. 2428-2434.
  9. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor–specific vascular endothelial growth factor mutants / H. Gille [et al.] // J. Biol. Chem. – 2001. – Vol. 276. – P. 3222-3230.
  10. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity / J. Tombran-Tink [et al.] // Neurosci. – 1995. – Vol. 15. – P. 4992-5003.
  11. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema / D. W. Chun [et al.] // Ophthalmology. – 2006. – Vol. 113. – P. 1706-1712.
  12. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema / Q. D. Nguyen [et al.] // Am. J. Ophthalmol. – 2006. – Vol. 142. – P. 961-969.
  13. READ–2 Study Group: Primary endpoint (6 months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study / Q. D. Nguyen [et al.] // Ophthalmology. – 2009. – Vol. 116. – P. 2175-2178.
  14. RESOLVE Study Group: Safety and efficacy of ranibizumab treatment in patients with diabetic macular edema: 12-month results of the RESOLVE study / A. Wolf [et al.] // ARVO Meeting. – Fort Lauderdable, 2009.
  15. Randomized trial evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema / M. J. Elman [et al.] // Ophthalmology. – 2010. – Vol. 117. – P. 1064-1077.
  16. Macugen Diabetic Retinopathy Study Group: A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema / E. T. Jr. Cunningham [et al.] // Ophthalmology. – 2005. – Vol. 112. – P. 1747-1757.
  17. Changes in retinal neovascularization after pegaptanib therapy in diabetic individuals / A. P. Adamis [et al.] // Ophthalmology. – 2006. – Vol. 113. – P. 23-28.
  18. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy / V. H. Gonzales [et al.] // Br. J. Ophthalmol. – 2009. – Vol. 93. – P. 1474-1478.
  19. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin) / J. Shahar [et al.] // Retina. – 2006. – Vol. 26. – P. 262-269.
  20. Testing intravitreal toxicity of bevacizumab (avastin) / R. P. A. Manzano [et al.] // Retina. – 2006. – Vol. 26. – P. 257-261.
  21. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema / I. U. Scott [et al.] // Ophthalmology. – 2007. – Vol. 114. – P. 1860-1867.
  22. Efficacy of 1, 25 vs. 2, 5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial / D. S. Lam [et al.] // Retina. – 2009. – Vol. 29. – P. 292-299.
  23. Long-term effect of intravitreal bevacizumab in patients with chronic diffuse diabetic macular edema / D. Kook [et al.] // Retina. – 2008. – Vol. 28 – P. 1053-1060.
  24. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema / M. Soheilian [et al.] // Ophthalmology. – 2009. – Vol. 116. – P. 1142-1150.
  25. Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy / R. L. Avery [et al.] // Ophthalmology. – 2006. – Vol. 113. – P. 1695.el-15.
  26. Intravitreal bevacizumab for persistent new vessels in diabetic retinopathy (IBEPE study) / R. Jorge [et al.] // Retina. – 2006. – Vol. 26. – P. 1006-1013.
  27. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy / S. Moradian [et al.] // Graefes. Arch. Clin. Exp. Ophthalmol. – 2008. – Vol. 246. – P. 1699-1705.
  28. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous haemorrhage / Y. H. Huang [et al.] // Retina. – 2009. – Vol. 29. – P. 1134-1140.
  29. Cytokine traps: multi-component, high-affinity blocker of cytokine action / A. N. Economides [et al.] // Nat. Med. – 2003. – Vol. 9. – P. 47-52.
  30. VEGF Trap: a VEGF blocker with potent antitumor effects / J. Holash [et al.] // Proc. Natl. Acad. Sci. USA. – 2002. – Vol. 99. – P. 11393-11398.
  31. Stewart, M. W. Predicted biological activity of intravitreal VEGF Trap / M. W. Stewart, P. J. Rosenfeld // Br. J. Ophthalmol. – 2008. – Vol. 92. – P. 667-668.
  32. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-eye in patients with diabetic macular edema / D. V. Do [et al.] // Br. J. Ophthalmol. – 2009. – Vol. 93. – P. 144-149.
  33. Singerman, L. J. Intravitreal bevasiranib in exudative age-related macular degeneration or diabetic macular edema / L. J. Singerman // 25-th Annual Meeting of the American Society of Retina Specialists, Indian Wells, December 1–5, 2007.
  34. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis / X. Zhu [et al.] // Am. J. Kidney. Dis. – 2007. – Vol. 49. – P. 186-193.
  35. Scott, I. U. Reducing the risk of endophthalmitis following intravitreal injections / I. U. Scott, H. W. Jr. Flynn // Retina. – 2007. – Vol. 27. – P. 10-12.
  36. Endophthalmitis associated with intravitreal anti–vascular endothelial growth factor therapy injections in an office setting / P. Suman [et al.] // Am. J. Ophthalmol. – 2008. – Vol. 145. – P. 879-882.
  37. Pegaptanib for neovascular age-related macular degeneration / E. S. Gragoudas [et al.] // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2805-2816.
  38. Ranibizumab versus verteporfin for neovascular age–related macular degeneration / D. M. Brown [et al.] // N. Engl. J. Med. – 2006. – Vol. 355. – P. 1432-1444.
  39. Ranibizumab for neovascular age–related macular degeneration / P. J. Rosenfeld [et al.] // N. Engl. J. Med. – 2006. – Vol. 355. – P. 1419-1431.
Адрес для корреспонденции:
220013, Республика Беларусь, г. Минск, ул. П. Бровки, д. 3, кор. 3, Белорусская медицинская академия последипломного образования, кафедра офтальмологии,
e-mail: ophth.malinovskaya@mail.ru,
Малиновская И.И.
Контакты | ©Витебский государственный медицинский университет, 2007